HomeAI · summaries
Storia in 2 fonti
Alumis’ TYK2 drug fails in key lupus study
Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Alumis’ TYK2 drug fails in key lupus study
Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.
- ·
endpoints.news
Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward'
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward Phase 3 talks with the FDA.